| human | Q5 |
| P735 | given name | Jasmin | Q18113540 |
| Jasmin | Q18113540 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q47286594 | A model for predicting effect of treatment on progression-free survival using MRD as a surrogate endpoint in CLL. |
| Q38866636 | Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial |
| Q50099521 | Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia |
| Q39154824 | Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). |
| Q39227223 | Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia |
| Q33396737 | Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group |
| Q90986748 | Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial |
| Q33402713 | Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group |
| Q89926249 | Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial |
| Q90647570 | CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia |
| Q49714232 | CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia |
| Q40188830 | Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes |
| Q47387422 | Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: Power, time-to-analysis, and operational aspects |
| Q27853387 | Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy |
| Q40301879 | Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia |
| Q34418874 | Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia |
| Q91685342 | Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction |
| Q89767703 | Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial |
| Q39302484 | Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective |
| Q37079102 | Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota |
| Q41351036 | Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group |
| Q45779169 | Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual |
| Q39153618 | FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia |
| Q40662825 | First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri |
| Q92993187 | Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1 regulated transcription |
| Q92991692 | High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia |
| Q91725442 | International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia |
| Q41997564 | Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study |
| Q51740147 | Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. |
| Q89770415 | Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) |
| Q39005118 | Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial |
| Q41041090 | Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group |
| Q92740078 | Machine learning can identify newly diagnosed patients with CLL at high risk of infection |
| Q50859722 | Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. |
| Q92924704 | Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL) |
| Q39714436 | Mutations driving CLL and their evolution in progression and relapse |
| Q47786604 | NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib |
| Q91572061 | New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance |
| Q36779681 | Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). |
| Q93263205 | Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia |
| Q91842078 | Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL |
| Q90613851 | Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax |
| Q92265946 | Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG) |
| Q89637413 | Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group |
| Q61804713 | Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab |
| Q45737543 | Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group |
| Q92615045 | Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia |
| Q92048839 | Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials |
| Q38986156 | The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression |
| Q64263185 | The Treatment of Chronic Lymphatic Leukemia |
| Q90465397 | Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study |
| Q41158692 | Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia |
| Q92539522 | Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions |
| Q42348732 | Venetoclax and obinutuzumab in chronic lymphocytic leukemia |
Search more.